首页EVGN • NASDAQ
add
Evogene Ltd
相关资讯
财务信息
损益表
收入
净收入
| (USD) | 2024年12月info | 年同比变化 |
|---|---|---|
收入 | 161.10万 | 178.72% |
经营支出 | 592.30万 | -24.14% |
净收入 | 42.70万 | 106.47% |
净利润率 | 26.51 | 102.32% |
每股收益 | 0.06 | 104.62% |
息税折旧摊销前利润 | -447.40万 | 35.76% |
有效税率 | 350.00% | — |
资产负债表
总资产
负债总额
| (USD) | 2024年12月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 1531.10万 | -50.71% |
总资产 | 3986.40万 | -21.99% |
负债总额 | 2502.60万 | 11.64% |
权益总额 | 1483.80万 | — |
发行在外的股份 | 651.46万 | — |
市净率 | -4.52 | — |
资产回报率 | -31.68% | — |
资本回报率 | -83.71% | — |
现金流
现金净变动
| (USD) | 2024年12月info | 年同比变化 |
|---|---|---|
净收入 | 42.70万 | 106.47% |
来自运营的现金 | -520.70万 | 12.12% |
投资现金 | 875.80万 | 1,594.54% |
融资现金 | 44.00万 | 399.32% |
现金净变动 | 398.40万 | 160.74% |
自由现金流 | -919.62万 | -148.92% |
简介
Evogene is a computational biology company based in Israel, specializing in predictive biology platforms that leverage artificial intelligence and machine learning for life-science product development. Evogene's platforms focus on designing novel microbes, small molecules, and genetic elements for use in pharmaceuticals, agriculture, and related industries. In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
CEO
成立时间
2002
员工数量
117
